SPRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ARS Pharmaceuticals Inc (SPRY) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The lack of positive financial performance, weak technical indicators, and absence of significant positive catalysts make it unsuitable for a long-term investment at this time.
The technical indicators show a bearish trend with SMA_200 > SMA_20 > SMA_5, MACD histogram below 0 and negatively contracting, and RSI in the neutral zone at 59.303. The stock is trading near its pivot level of 8.181, with resistance at 8.909 and support at 7.453. Overall, the technical outlook is weak.
Hedge funds are increasing their positions, with a 326% increase in buying over the last quarter.
No recent news or significant insider trading activity. The stock has a 50% chance of declining by -1.43% in the next day, -2.45% in the next week, and -7.65% in the next month. Financial performance has significantly deteriorated, with revenue, net income, and EPS all showing sharp YoY declines.
In Q4 2025, revenue dropped by -67.56% YoY to $28.09M, net income fell by -182.76% YoY to -$41.32M, and EPS declined by -200% YoY to -0.42. Gross margin also dropped by -21.12% YoY to 78.09%. These metrics indicate poor financial health.
No recent analyst rating or price target changes available for evaluation.
